EluNIR Drug-Eluting Stent System
Cordis, a Cardinal Health company
- Novel metallic spring tip for superior deliverability
- Narrowest struts (40 μm) on the market in the United States
- Optimal conformability and vessel support
- Elastomeric coating and outstanding surface integrity
- Elutes ridaforolimus, a high therapeutic index limus drug
Cordis, a Cardinal Health company, and Medinol’s EluNIR drug-eluting stent (DES) recently received US Food and Drug Administration approval for the treatment of patients with narrowing or blockages to their coronary arteries.
The EluNIR stent system has a low footprint cobalt-chromium design with ultra-narrow 40-µm struts, which help clinicians easily deliver this new DES in highly complex anatomy and disease. The stent system features a novel spring tip for superior deliverability in challenging anatomies. The DES’s adaptive cell size is designed for optimal scaffolding and uniform drug dosing while preventing tissue prolapse. It is the first and only elastomeric DES available.
In BIONICS, a randomized clinical trial with 1,919 patients from 76 sites in eight countries, the EluNIR DES showed a 5.4% target lesion failure and a 0% rate of late stent thrombosis at 12 months.
“Experience with the EluNIR stent in broad patient and lesion complexities representative of routine practice mirrors its performance observed in the BIONICS trial,” said David E. Kandzari, MD, Director of Interventional Cardiology and Chief Scientific Officer, Piedmont Heart Institute in Atlanta, Georgia. “The stent system demonstrates exceptional deliverability and acute procedural results that are further supported by favorable clinical efficacy and safety.”
The EluNIR DES is also CE Marked and is currently used by physicians in Europe. EluNIR is distributed in the United States by Cordis, a Cardinal Health company.